<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="441">
  <stage>Registered</stage>
  <submitdate>18/03/2004</submitdate>
  <approvaldate>18/03/2004</approvaldate>
  <nctid>NCT00079911</nctid>
  <trial_identification>
    <studytitle>A Clinical Research Study For The Suppression And Treatment Of Genital Herpes Infection In HIV-Infected Persons</studytitle>
    <scientifictitle>An International, Randomized, Double-Blind, Placebo-Controlled Study of Valaciclovir for the Suppression and Episodic Treatment of Genital HSV Infection in HIV-Infected Persons With CD4+ Lymphocyte Count &lt;100 Cells/mm3.</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>100181</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Herpes Genitalis</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Sexually transmitted infections</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - valacyclovir hydrochloride

Experimental: Suppressive + Episodic Therapy - Valaciclovir (VAL) 500mg twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 days or 10 days, when required for treatment of a genital herpes recurrence.

Placebo Comparator: Episodic Therapy - Matching placebo twice daily for 6 months, and episodic treatment with VAL 1000mg twice daily for 5 or 10 days, when required for treatment of a genital herpes recurrence.


Treatment: drugs: valacyclovir hydrochloride
valacyclovir hydrochloride

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Adverse Events - The nature and incidence of adverse events, by treatment group, reported during the 6-month study will be summarized.</outcome>
      <timepoint>Up to 6 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of recurrence of genital HSV - Secondary outcome measures are the proportion of subjects recurrence-free of genital HSV at 6 months, and the time to first culture-positive recurrence of genital HSV.</outcome>
      <timepoint>Up to 6 months</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to first culture-positive recurrence of genital HSV - Secondary outcome measures are the proportion of subjects recurrence-free of genital HSV at 6 months, and the time to first culture-positive recurrence of genital HSV.</outcome>
      <timepoint>Up to 6 months</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  CD4+ lymphocyte count &lt;100cells/mm3 at the screening visit.

          -  Documented history of HIV infections

          -  Must have received stable, combination anti HIV drugs for at least 4 months
             immediately prior to participation, and per the investigator, are unlikely to require
             change in anti-HIV drugs during the six-month study.

          -  Laboratory confirmation of genital herpes (a positive Herpes Simplex Virus-2 antibody
             test).

          -  3 or more outbreaks of genital herpes in the previous 12 months if not on genital
             herpes medicines currently.

          -  3 or more outbreaks of genital herpes per year in the period prior to beginning of
             treatment for chronic genital herpes.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Kidney diseases.

          -  Liver diseases.

          -  Known allergic reactions to VALTREX (valaciclovir), ZOVIRAX (acyclovir), FAMVIR
             (famciclovir), or CYTOVENE (ganciclovir).

          -  Vomiting syndrome.

          -  Must be willing to discontinue taking current genital herpes medicines 1 week prior to
             participation.

          -  Active AIDS-indicator conditions, as defined by CDC Category C.

          -  Other protocol inclusion and exclusion criteria to be evaluated by the research
             physician.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>14/03/2004</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>7</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>15/10/2004</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>GSK Investigational Site - Darlinghurst</hospital>
    <postcode>2010 - Darlinghurst</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Hong Kong</country>
      <state>Kowloon Bay</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>GlaxoSmithKline</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This clinical research study will be an international trial evaluating the safety and
      effectiveness of a marketed drug compared to placebo (like a sugar pill) for the suppression
      of repeated genital herpes infections in HIV-infected subjects with CD4+ count &lt;100
      cells/mm3.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00079911</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>GSK Clinical Trials</name>
      <address>GlaxoSmithKline</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>